Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (241)	7/9/2004 3:47:38 AM
From: Thomas	Read Replies (2) \| Respond to of 671

Is this progress on the delivery question or just a good sounding press release? Thanks for any thoughts. Cheers, Thomas Apharmas Launches New DNA/RNA and siRNA transfection Reagent America Pharma Source (Apharmas) has launched next generation in vitro transfection reagents, Easy-Transgater and Easy-Transgater-si, specifically developed for the delivery of DNA/RNA and siRNA into difficult-to-transfect cell lines as well as a broad range of mammalian cells. Based on new lipid-conjugation technology, these products have superior transfection efficiency with low cytotoxicity and no sera interference. Gaithersburg, MD (PRWEB) July 9, 2004 -- America Pharma Source, LLC (Apharmas) today announced that it has launched next generation in vitro transfection reagents, Easy-Transgater and Easy-Transgater-si, specifically developed for the delivery of DNA/RNA and siRNA into difficult-to-transfect cell lines as well as a broad range of mammalian cells. These products are based on new lipid-conjugation technology and have superior transfection efficiency with low cytotoxicity and no sera interference. Their simple protocols enable researchers to get satisfactory results easily and fast. Along with the introduction of these products, Apharmas also announced the launch of pre-coated ready-to-transfect plates (96-well, 24-well and 6-well) for high-throughput applications such as screening and gene silencing. "To effectively deliver genes to cells, both in vitro and in vivo, still faces many technical problems and challenges, especially in RNAi and gene therapy area. Apharmas is working hard to develop gene/drug delivery systems and provide more powerful transfection tools. Easy-Transgater series are the result of our initial efforts,” said Dr. Frank F. Yu, CEO of America Pharma Source. “With the introduction of these products, researchers now have better choices for difficult-to-transfect cell lines and high-throughput applications. More importantly, comparing to the most popular transfection products, Easy-Transgater series can save 20% to 40% reagent costs. Apharmas believes that will greatly benefit those academic institutes, universities and small biotech companies. We are continuing to offer more innovative products for transfection into primary cells to satisfy the growing demand for siRNA and DNA/RNA delivery tools.” About Apharmas: America Pharma Source (Apharmas) is a growing biopharma company to provide products and services to pharmaceutical and biotech companies, universities and non-profit organizations to accelerate their bioscience research and drug development efforts. Working with strategic research partners, Apharmas also is developing new technologies and products on drug delivery system to discover new combinations and seek a balanced therapy. Founded in 2000, Apharmas has expanded its presence in Asia market and established a R&D and manufacture facility in China. For more information about Apharmas, visit the company’s web site at www.apharmas.com.